SI-BONE, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SI-BONE, Inc. on August 21, 2026, with the earliest event reported on that date. The filing discloses a voluntary product recall and a lease amendment for the company's corporate headquarters in Santa Clara, California.
Key Financial Metrics and Material Changes
The filing does not provide comprehensive financial statements, revenue, profit, or liquidity metrics. Specific financial impacts are limited to the following:
- Recall Costs: The company expects to record an aggregate gross charge of up to approximately $150,000 in the third and fourth quarters of 2026 within cost of goods sold.
- Lease Extension: The company entered into a Fourth Amendment to its office lease extending the term for one month (October 1, 2026, to October 31, 2026) with a base rent of $43,696 per month.
- Revenue Impact: Management does not believe the recall will impact third-quarter revenue.
Guidance, Outlook, and Risks
Product Recall (Item 8.01):
- Scope: A voluntary recall of 98 iFuse TORQ implants from specific lots due to tube packaging failure potentially compromising sterility.
- Patient Impact: Two implants had been implanted in patients; no infections or adverse events have been reported as of the filing date.
- Inventory Impact: Approximately 3,900 implants require repackaging and re-sterilization. The company does not anticipate a material impact on the ability to supply physicians due to available on-hand inventory.
- Regulatory Status: The company submitted a report to the FDA recommending a Class II recall classification.
- Actual recall costs may exceed the estimated $150,000.
- There is no assurance that costs will be recovered from the tube manufacturer.
- The recall scope could expand to include additional lots or products.
- The FDA may classify the recall differently or take other regulatory actions.
- Potential for future product liability claims or adverse events.
Investor Verification Checklist
- Verify the final classification of the recall by the FDA and any subsequent regulatory actions.
- Monitor the actual financial charge recorded in Q3 and Q4 2026 earnings reports to confirm if it stays within the $150,000 estimate.
- Track any reports of adverse events or infections related to the two implanted devices.
- Confirm whether the company successfully recovers costs from the tube packaging manufacturer.
- Review future filings for any expansion of the recall scope beyond the initial 98 distributed units and 3,900 quarantined units.